Mazdutide vs Ipamorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
MazdutideGrowth Hormone Peptides
Ipamorelin- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
- Half-Life
- ~7 days
- 2 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 100–300 mcg
- Frequency
- Once weekly
- Once to twice daily
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Increases lean muscle mass
- Enhances fat loss
- Improves recovery time
- Strengthens bones and joints
- Better sleep quality and REM sleep
- Enhanced skin elasticity
- Minimal impact on hunger or cortisol
- No cortisol or prolactin spike
- Clean GH release suitable for long-term protocols
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Injection site irritation
- Temporary water retention (mild)
- Possible hunger increase (milder than GHRP-6)
- Numbness or tingling in extremities (rare)
- Stacks With
- —
- —